Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Five Star Equities Issues New Research Reports on ATOS, CTIC, DAR and MTRN

DAR, MTRN, ATOS

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.

Atossa Genetics Inc. (NASDAQ: ATOS) shares dropped 46.43 percent to close at $2.85 a share Monday. The stock traded between $2.54 and $3.18 on volume of 3.59 million shares traded. The company announced a voluntary recall of its ForeCYTE Breast Health Test and the Mammary Aspiration Specimen Cytology Test (MASCT) device. Shares of Atossa Genetics have fallen approximately 27.0 percent year-to-date.

Get more information on Atossa Genetics free access to the in-depth equity report at:
www.FiveStarEquities.com/ATOS

Cell Therapeutics Inc. (NASDAQ: CTIC) shares jumped 22.64 percent to close at $1.95 a share Monday. The stock traded between $1.68 and $1.95 on volume of 12.80 million shares traded. The company announced an agreement with the FDA on a Special Protocol Assessment for the planned pivotal Phase 3 trial of pacritinib in myelofibrosis. Shares of Cell Therapeutics have gained approximately 50.0 percent year-to-date.

Get more information on Cell Therapeutics and free access to the in-depth equity report at:
www.FiveStarEquities.com/CTIC

Darling International Inc. (NYSE: DAR) shares gained 2.31 percent to close at $20.80 a share Monday. The stock traded between $20.20 and $21.21 on volume of 1.98 million shares traded. The company announced that it has agreed to acquire Vion Ingredients, a division of Vion Holding N.V. (a member of the Vion Food Group), for approximately €1.6 billion in cash. Shares of Darling International have gained approximately 30.0 percent year-to-date.

Get more information on Darling International and free access to the in-depth equity report at:
www.FiveStarEquities.com/DAR

Materion Corp. (NYSE: MTRN) shares fell 10.89 percent to close at $28.80 a share Monday. The stock traded between $28.55 and $30.19 on volume of 478,293 shares traded. The company announced that results for the third quarter are expected to be weaker than previously expected. Shares of Materion have gained approximately 11.0 percent year-to-date.

Get more information on Materion and free access to the in-depth equity report at:
www.FiveStarEquities.com/MTRN

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
info@fivestarequities.com